Adverse events (minor bleeding) · people hospitalised with COVID‐19
Higher‐dose anticoagulants leads to higher adverse events (minor bleeding) compared with lower‐dose anticoagulants (high certainty).
1 finding from 1 review
Clavien‐Dindo grade ≤ 2 complications8 · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
NBI + WLC TURBT showed no clear difference in minor adverse event (Clavien‐Dindo grade I and II) compared with WLC TURBT (low certainty).
1 finding from 1 review
Change in sputum P aeruginosa density at end of treatment (cfu/g) · adults and children with cystic fibrosis
Summary of findings: single showed no clear difference in change in sputum P aeruginosa density at end of treatment (cfu/g) compared with combination intravenous anti‐pseudomonal antibiotic therapy (moderate certainty).
2 findings from 1 review
Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged less than 11 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged 5 to 49 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged over 6 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events Defined as any adverse event within 8 weeks of surgery that does not require further intervention · people with intermittent exotropia, aged 3 to < 11 years
Bilateral lateral rectus recession showed no clear difference in minor adverse events Defined as any adverse event within 8 weeks of… compared with unilateral lateral rectus recession with medial rectus resection (low certainty).
1 finding from 1 review
Intervention not reported
Case cross‐over ‐ Urabe or Hoshino · children 9 months to 15 years old
The intervention may leads to higher case cross‐over ‐ Urabe or Hoshino (low certainty).
1 finding from 1 review
Intervention not reported
Cohort study ‐ rhinoconjunctivitis · children 9 months to 15 years old
The intervention showed no clear difference in cohort study ‐ rhinoconjunctivitis (low certainty).
1 finding from 1 review
Minor haemorrhagic events (duration of · patients with acute pulmonary embolism
Thrombolytic therapy may leads to higher minor haemorrhagic events (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in minor bleeding compared with no prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in minor bleeding compared with heparin (moderate certainty).
1 finding from 1 review
Minor bleeding · patients with the initial treatment of venous thromboembolism in patients with cancer
Dalteparin showed no clear difference in minor bleeding compared with tinzaparin (low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: minor (hirsutism) · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin may leads to higher adverse events: minor (hirsutism) compared with oral azathioprine (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).
1 finding from 1 review